Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898598 · ClinicalTrials.gov registry record · Phase 2
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01898598 is a Phase 2 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 18 participants.
The verdict
NCT01898598, a Phase 2 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in participants with basal cell carcinoma.
Interventions
- DRUG Placebo
- DRUG Vismodegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-01-23 |
| Est. Completion | 2016-01-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01898598
The ClinicalTrials.gov registry entry for NCT01898598 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01898598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01898598 about?
NCT01898598 is a clinical study titled "A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma". This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in participants with basal cell carcinoma.
What is the current status of trial NCT01898598?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2014-01-23. Estimated completion is 2016-01-26.
What interventions are being tested in trial NCT01898598?
The interventions under investigation include: Placebo (DRUG), Vismodegib (DRUG).
Who is sponsoring clinical trial NCT01898598?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.